ResMed Inc (RMD)

The analysis of ResMed Inc’s days of sales outstanding (DSO) over the specified period reveals fluctuations indicating changes in the company’s receivables collection efficiency. As of June 30, 2021, the DSO was approximately 70.14 days, reflecting the average number of days it took for the company to collect its receivables. By June 30, 2022, the DSO decreased significantly to 58.75 days, suggesting an improvement in collection processes or a shift in credit policies that facilitated faster receivables turnover.

However, the subsequent period up to June 30, 2023, shows a slight increase to 60.93 days, indicating a modest slowdown in receivables collection efficiency. This upward trend continued into June 30, 2024, with DSO rising to 65.23 days, signaling a further elongation in the duration it takes to convert receivables into cash. The most recent data point for June 30, 2025, shows a DSO of 66.63 days, slightly higher than the previous year, suggesting a gradual return to longer collection periods.

Overall, the DSO trend demonstrates an initial improvement from 2021 to 2022, followed by a gradual increase through 2023 to 2025. This pattern could imply evolving credit terms, changes in customer payment behaviors, or strategic adjustments in receivables management. The incremental rise in DSO over the recent years warrants monitoring, as longer collection periods may impact liquidity and working capital management if the trend persists.

Peer comparison

Jun 30, 2025